HK1117569A1 - Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus - Google Patents
Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitusInfo
- Publication number
- HK1117569A1 HK1117569A1 HK08107630.3A HK08107630A HK1117569A1 HK 1117569 A1 HK1117569 A1 HK 1117569A1 HK 08107630 A HK08107630 A HK 08107630A HK 1117569 A1 HK1117569 A1 HK 1117569A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- type
- risk
- diabetes mellitus
- genetic variants
- diagnostic markers
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 abstract 1
- 238000012098 association analyses Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69217405P | 2005-06-20 | 2005-06-20 | |
| US75715506P | 2006-01-06 | 2006-01-06 | |
| PCT/IS2006/000014 WO2006137085A1 (en) | 2005-06-20 | 2006-06-16 | Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1117569A1 true HK1117569A1 (en) | 2009-01-16 |
Family
ID=37036993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08107630.3A HK1117569A1 (en) | 2005-06-20 | 2008-07-10 | Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7585630B2 (he) |
| EP (1) | EP1907569B1 (he) |
| JP (1) | JP5301987B2 (he) |
| KR (1) | KR101374304B1 (he) |
| CN (1) | CN101238222B (he) |
| AU (1) | AU2006260477B2 (he) |
| BR (1) | BRPI0612301A2 (he) |
| CA (1) | CA2612475C (he) |
| EA (1) | EA016397B1 (he) |
| HK (1) | HK1117569A1 (he) |
| IL (1) | IL188147A (he) |
| MX (1) | MX2007015848A (he) |
| NO (1) | NO341910B1 (he) |
| NZ (1) | NZ564285A (he) |
| WO (1) | WO2006137085A1 (he) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| CN101238222B (zh) * | 2005-06-20 | 2013-04-10 | 解码遗传学私营有限责任公司 | 作为2型糖尿病风险诊断标记物的tcf7l2基因的遗传变异体 |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| JP2010510804A (ja) * | 2006-11-30 | 2010-04-08 | デコード・ジェネティクス・イーエイチエフ | ２型糖尿病の遺伝的感受性変異体 |
| US20080287650A1 (en) * | 2007-03-01 | 2008-11-20 | Avi Tovi | High purity peptides |
| CA2685816A1 (en) * | 2007-04-30 | 2008-11-06 | Compugen Ltd. | Allelic polymorphism associated with diabetes |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| NZ598009A (en) * | 2009-07-10 | 2013-11-29 | Decode Genetics Ehf | Genetic markers associated with risk of diabetes mellitus |
| KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| AU2014236386A1 (en) * | 2013-03-14 | 2015-10-01 | The Children's Hospital Of Philadelphia | TCF7L2 variant and methods of use thereof in diagnostic and drug screening assays |
| RU2521202C1 (ru) * | 2013-04-12 | 2014-06-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ прогнозирования риска развития сахарного диабета второго типа у больных гипертонической болезнью |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| CN103882127B (zh) * | 2014-03-13 | 2016-03-16 | 河北联合大学 | 用于预测患2型糖尿病肾病发生风险的试剂盒 |
| WO2016201438A1 (en) * | 2015-06-11 | 2016-12-15 | The Children's Hospital Of Philadelphia | New targets modulated by a casual variant of type 2 diabetes (t2d) embedded within the tcf7l2 gene and methods of use thereof for identifying agents having efficacy for the treatment of type 2 diabetes and other metabolic disorders |
| MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
| CN109182508A (zh) * | 2018-10-22 | 2019-01-11 | 北京华夏时代生物工程有限公司 | Tcf7l2基因单核苷酸多态性的荧光原位杂交测序方法 |
| TWI702292B (zh) * | 2018-12-28 | 2020-08-21 | 薩摩亞商康多富國際有限公司 | 個人化新陳代謝疾病保健食品組合的決定方法及非暫態電腦可讀取儲存媒體 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| CA1215904A (en) * | 1983-01-10 | 1986-12-30 | David E. Kohne | Method for detection identification and quantitation of non-viral organisms |
| US5288611A (en) * | 1983-01-10 | 1994-02-22 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating organisms and viruses |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE3534934A1 (de) * | 1985-10-01 | 1987-04-02 | Draegerwerk Ag | Kolorimetrisches gasdosimeter |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5176996A (en) * | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5264564A (en) * | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5384261A (en) * | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5858659A (en) * | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| US6153618A (en) | 1996-10-11 | 2000-11-28 | Chiron Corporation | Inhibitors of glycogen synthase 3 kinase |
| JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | グリコーゲンシンターゼキナーゼ３のインヒビター |
| US6512102B1 (en) | 1998-12-31 | 2003-01-28 | Chiron Corporation | Compositions and methods of diagnosis and treatment using casein kinase I |
| ATE303383T1 (de) | 1999-12-17 | 2005-09-15 | Chiron Corp | Bizyklische inhibitoren von glycogen synthase kinase 3 |
| EP1237880B1 (en) | 1999-12-17 | 2008-01-23 | Novartis Vaccines and Diagnostics, Inc. | Pyrazine based inhibitors of glycogen synthase kinase 3 |
| WO2002010357A2 (en) | 2000-07-27 | 2002-02-07 | Chiron Corporation | Gsk3 polypeptides |
| AU785425B2 (en) * | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
| WO2003004488A1 (en) | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| AU2002324649A1 (en) * | 2001-08-04 | 2003-02-24 | General Hospital Corporation | Haplotype map of the human genome and uses therefor |
| WO2003024447A1 (en) * | 2001-09-20 | 2003-03-27 | Smithkline Beecham Corporation | Inhibitors of glycogen synthase kinase-3 |
| US20040072831A1 (en) | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| US20040023237A1 (en) * | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
| US6762185B1 (en) | 2002-03-01 | 2004-07-13 | Choongwae Pharma Corporation | Compounds useful for treatment of cancer, compositions containing the same, and methods of their use |
| EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| EP2573079A3 (en) | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
| EP1549144A4 (en) | 2002-10-04 | 2010-01-06 | Univ California | METHODS OF TREATING CANCER BY INHIBITING WNT SIGNALING |
| AU2003290562A1 (en) * | 2002-11-01 | 2004-06-07 | Decode Genetics Ehf. | HUMAN TYPE II DIABETES GENE-SLIT-3 LOCATED ON CHROMOSOME 5q35 |
| US20040146870A1 (en) * | 2003-01-27 | 2004-07-29 | Guochun Liao | Systems and methods for predicting specific genetic loci that affect phenotypic traits |
| CN1548553A (zh) * | 2003-05-21 | 2004-11-24 | 中国医学科学院基础医学研究所 | 用于预测2型糖尿病易感性的试剂盒及引物 |
| US6991110B2 (en) * | 2003-07-02 | 2006-01-31 | Inficon, Inc. | Package for storing sensor crystals and related method of use |
| US7531320B2 (en) | 2003-08-28 | 2009-05-12 | Choongwae Pharma Corporation | Modulation of β-catenin/TCF-activated transcription |
| CN101238222B (zh) * | 2005-06-20 | 2013-04-10 | 解码遗传学私营有限责任公司 | 作为2型糖尿病风险诊断标记物的tcf7l2基因的遗传变异体 |
-
2006
- 2006-06-16 CN CN2006800221296A patent/CN101238222B/zh not_active Expired - Fee Related
- 2006-06-16 WO PCT/IS2006/000014 patent/WO2006137085A1/en active Application Filing
- 2006-06-16 BR BRPI0612301-5A patent/BRPI0612301A2/pt not_active Application Discontinuation
- 2006-06-16 EP EP06745230.0A patent/EP1907569B1/en active Active
- 2006-06-16 EA EA200800087A patent/EA016397B1/ru not_active IP Right Cessation
- 2006-06-16 MX MX2007015848A patent/MX2007015848A/es active IP Right Grant
- 2006-06-16 NZ NZ564285A patent/NZ564285A/en not_active IP Right Cessation
- 2006-06-16 US US11/454,296 patent/US7585630B2/en active Active
- 2006-06-16 AU AU2006260477A patent/AU2006260477B2/en not_active Ceased
- 2006-06-16 CA CA2612475A patent/CA2612475C/en active Active
- 2006-06-16 KR KR1020087001376A patent/KR101374304B1/ko active IP Right Grant
- 2006-06-16 JP JP2008517701A patent/JP5301987B2/ja not_active Expired - Fee Related
-
2007
- 2007-12-13 IL IL188147A patent/IL188147A/en active IP Right Grant
-
2008
- 2008-01-21 NO NO20080389A patent/NO341910B1/no not_active IP Right Cessation
- 2008-07-10 HK HK08107630.3A patent/HK1117569A1/xx not_active IP Right Cessation
-
2009
- 2009-06-15 US US12/456,381 patent/US20090275043A1/en not_active Abandoned
-
2011
- 2011-11-11 US US13/294,802 patent/US20120149016A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA016397B1 (ru) | 2012-04-30 |
| KR20080051128A (ko) | 2008-06-10 |
| US20090275043A1 (en) | 2009-11-05 |
| EP1907569A1 (en) | 2008-04-09 |
| EA200800087A1 (ru) | 2008-06-30 |
| IL188147A0 (en) | 2008-03-20 |
| NO341910B1 (no) | 2018-02-19 |
| US20060286588A1 (en) | 2006-12-21 |
| AU2006260477A1 (en) | 2006-12-28 |
| EP1907569B1 (en) | 2013-04-10 |
| JP5301987B2 (ja) | 2013-09-25 |
| AU2006260477B2 (en) | 2012-02-23 |
| NZ564285A (en) | 2010-03-26 |
| CN101238222A (zh) | 2008-08-06 |
| CA2612475C (en) | 2015-07-28 |
| NO20080389L (no) | 2008-01-21 |
| CN101238222B (zh) | 2013-04-10 |
| BRPI0612301A2 (pt) | 2009-01-27 |
| US20120149016A1 (en) | 2012-06-14 |
| KR101374304B1 (ko) | 2014-03-14 |
| AU2006260477A8 (en) | 2006-12-28 |
| IL188147A (en) | 2013-02-28 |
| US7585630B2 (en) | 2009-09-08 |
| WO2006137085A1 (en) | 2006-12-28 |
| CA2612475A1 (en) | 2006-12-28 |
| MX2007015848A (es) | 2008-04-22 |
| JP2008546403A (ja) | 2008-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1117569A1 (en) | Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus | |
| IL249715B (he) | N–בוטיל–דאוקסינוג'ירימיצין לשימוש כתרופה לטיפול במחלת פומפ בשילוב עם גורם תרפיית החלפת אנזים | |
| EP1904630A4 (en) | METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE | |
| IL225203A (he) | פוליפפטיד פקטור h משלים מבודד, 'שיטות להכנתו, שימושים שלו וגורם אשר מוריד את ביטויו או פעילותו | |
| WO2008117314A3 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| WO2006063704A3 (en) | Single nucleotide polymorphism (snp) associated to type ii diabetes | |
| WO2007131072A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| WO2008103470A3 (en) | Oncogenic-ras-signal dependent lethal compounds | |
| WO2007044413A3 (en) | Wwox gene, vectors containing the same, and uses in treatment of cancer | |
| MX2009005849A (es) | Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. | |
| WO2008065372A3 (en) | Modified erythropoietin polypeptides and uses thereof for treatment | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| WO2009038689A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| EP1948831A4 (en) | ALZHEIMER ASSOCIATED GENETIC POLYMORPHISMS, DETECTION METHOD AND USE THEREOF | |
| MX2010001993A (es) | Metodos y composiciones para diagnosticar una enfermedad. | |
| WO2011001135A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| WO2006099259A3 (en) | Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof | |
| WO2008065682A3 (en) | Genetic susceptibility variants of type 2 diabetes mellitus | |
| WO2007062380A3 (en) | Modulation of eif4e-bp2 expression | |
| WO2007120955A3 (en) | Genes affecting human memory performance | |
| WO2006063703A8 (en) | Single nucleotide polymorphism (snp) associated to type ii diabetes | |
| WO2007063405A3 (en) | Diagnosis and treatment of exocrine pancreatic dysfunction and diabetes using human cel gene | |
| WO2010008858A8 (en) | Use of iron-related pathways and genes for treatment and diagnosis of parkinson's disease | |
| WO2010011626A3 (en) | Pyridinyl modulators of ϒ-secretase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210611 |